BACKGROUND: Hepatitis B virus infection is a very common cause of chronic liver disease worldwide. It is estimated that 3% of Iranians are chronically infected with hepatitis B virus. Current population-based studies on both rural and urban prevalence of hepatitis B virus infection in Iran are sparse with results that do not always agree. We performed this study to find the prevalence of hepatitis B surface antigen, anti-hepatitis B core antibody, and associated factors in the general population of three provinces of Iran. METHODS: We randomly selected 6,583 subjects from three provinces in Iran, namely Tehran, Golestan, and Hormozgan. The subjects were aged between 18 and 65 years. Serum samples were tested for hepatitis B surface antigen and anti-hepatitis B core antibody. Various risk factors were recorded and multivariate analysis was performed. RESULTS: The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran was 2.6% and 16.4%, respectively. Predictors of hepatitis B surface antigen or anti-hepatitis B core antibody in multivariate analysis included older age, not having high-school diploma, living in a rural area, and liver disease in a family member. We did not find any significant differences between males and females. CONCLUSION: In spite of nationwide vaccination of newborns against hepatitis B virus since 1992, hepatitis B virus infection remains a very common cause of chronic liver disease in Iran which should be dealt with for at least the next 30-50 years.
BACKGROUND:Hepatitis B virus infection is a very common cause of chronic liver disease worldwide. It is estimated that 3% of Iranians are chronically infected with hepatitis B virus. Current population-based studies on both rural and urban prevalence of hepatitis B virus infection in Iran are sparse with results that do not always agree. We performed this study to find the prevalence of hepatitis B surface antigen, anti-hepatitis B core antibody, and associated factors in the general population of three provinces of Iran. METHODS: We randomly selected 6,583 subjects from three provinces in Iran, namely Tehran, Golestan, and Hormozgan. The subjects were aged between 18 and 65 years. Serum samples were tested for hepatitis B surface antigen and anti-hepatitis B core antibody. Various risk factors were recorded and multivariate analysis was performed. RESULTS: The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran was 2.6% and 16.4%, respectively. Predictors of hepatitis B surface antigen or anti-hepatitis B core antibody in multivariate analysis included older age, not having high-school diploma, living in a rural area, and liver disease in a family member. We did not find any significant differences between males and females. CONCLUSION: In spite of nationwide vaccination of newborns against hepatitis B virus since 1992, hepatitis B virus infection remains a very common cause of chronic liver disease in Iran which should be dealt with for at least the next 30-50 years.
Authors: Sadaf G Sepanlou; Arash Etemadi; Farin Kamangar; Alireza Sepehr; Akram Pourshams; Hossein Poustchi; Farhad Islami; Alireza Sadjadi; Dariush Nasrollahzadeh; Shahryar Semnani; Farrokh Saidi; Christian C Abnet; Bruce Ponder; Paul D Pharoah; Nicholas E Day; Paul Brennan; Paolo Boffetta; Sanford M Dawsey; Reza Malekzadeh Journal: Arch Iran Med Date: 2013-01 Impact factor: 1.354
Authors: Antonella Esposito; Chiara Sabia; Carmela Iannone; Giovanni F Nicoletti; Linda Sommese; Claudio Napoli Journal: Transfus Med Hemother Date: 2017-05-05 Impact factor: 3.747
Authors: Masoud M Malekzadeh; Hooman Khademi; Akram Pourshams; Arash Etemadi; Hossein Poustchi; Mohammad Bagheri; Masoud Khoshnia; Amir Ali Sohrabpour; Ali Aliasgari; Elham Jafari; Farhad Islami; Shahryar Semnani; Christian C Abnet; Paul D P Pharoah; Paul Brennan; Paolo Boffetta; Sanford M Dawsey; Reza Malekzadeh; Farin Kamangar Journal: Am J Gastroenterol Date: 2013-10-22 Impact factor: 10.864
Authors: Mohammad Ali Assarehzadegan; Mehri Ghafourian Boroujerdnia; Khodamorad Zandian Journal: Iran Red Crescent Med J Date: 2012-08-30 Impact factor: 0.611